^
    Back
    Association details:
    Biomarker:RPS6 underexpression
    Cancer:Cutaneous T-cell Lymphoma
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

    Published date:
    11/06/2019
    Excerpt:
    ...phase II study for pts with relapsed or refractory (RR) PTCL or CTCL...The most notable finding was that responders to ruxolitinib had markedly lower pS6 expression within tumor cells of pre-treatment biopsies…
    DOI:
    10.1182/blood-2019-125017